Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

124 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

70 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order …

16 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities. IndiaCHIP, Genomics, Genomics - Emerging markets, Genomics - R&D, Genomics Data Platform, Genomics - India, bioinformatics, and …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology

SINTOTEST® supports rheumatologists in optimizing the prescription of rheumatology biotherapies Sinnovial is a biotechnology company that develops personalized medicine devices to improve the management of chronic inflammatory rheumatism (RIC) in rheumatology (rheumatoid arthritis, ankylosing spondylarthritis, in particular). Our mission: to improve the quality of life of patients by maximizing the chances of success of their biotherapy treatment. Our goal: to provide the doctor with a therapeutic orientation assistance system that allows him, in real time, to optimize the selection of biotherapy. "The right treatment, at the right patient, at the right time!" »» Biotechnology, rheumatology, medtech, and chronic inflammatory rheumatism

35 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

168 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creating breakthrough therapies. Changing lives. Antion Biosciences SA (Antion) is a Swiss biopharmaceutical company developing novel gene and gene-modified cell therapies to treat and cure diseases with significant unmet medical needs. Our proprietary technologies allow for the creation of multimodal treatments that aim to substantially enhance clinical safety and efficacy. We have a number of products in preclinical development, and it is our mission to translate our proprietary technologies into meaningful therapies for the benefit of patients. We are fully committed to creating high-value therapeutic assets, while developing strategies to ensure broad accessibility of our treatments, especially to resource poor …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience's expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Your expert drug development partner, guiding your asset to and through the clinic If you’ve only got one shot at getting your drug to the clinic, we’ll help you make it the best one. At Leads to Development, we enable biotech companies to bring novel drugs to and through clinical trials as efficiently and smoothly as possible. With decades of experience and more than 160 projects under our belt throughout Europe and the US, our team provides comprehensive end-to-end support across all areas of new drug development. Our backgrounds are in biotech rather than big pharma, so we understand the …

109 similar entities Type: SMB Startup Activities: biotech deeptech Technologies: Synthetic Biology

Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

160 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Scale Drug Discovery with Quantum-inspired Physics and AI AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. AQEMIA is based in Paris and London. We are growing and hiring! Check our …

32 similar entities Tags: FrenchTech120 FrenchTech2030 Type: Startup Activities: deeptech healthtech Technologies: A.I. Generative A.I. Synthetic Biology

Reimagining drug repositioning At MedInsights, we are dedicated to bringing optimized therapeutic options for patients suffering from rare diseases. Our internal drug repositioning engine, NexusRx, serves as a cornerstone for our discovery research, employing internal sets of proprietary algorithms to detect unknown and unforeseen relationships between disease-targets-drugs. This opens up preclinical validation opportunities which we perform in close partnerships with our academic collaborators. We envision to perform clinical trials and bring therapeutics from lab to bed side. Crunchbase profile: https://www.crunchbase.com/organization/medinsights-0569 Biotech, Data Science, and Healthcare

133 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Data Analytics

Supporting Healthcare Innovation R.G.L Research is a contract research organization (CRO) providing expertise and reliable support to the pharmaceutical industries for conducting Clinical Trials. Our clients and partners include pharmaceuticals, biotechnologies, startups, academic and government organization. R.G.L Research is providing tailored and quality services to help clients and partners bend the cost and time curve of drug development to deliver new alternative product and innovative treatment to improve patients quality of life. R.G.L Research has vast professional experience and academic knowledge in performing clinical trials in Israel as well as developing health product in diverse therapeutic areas of medicine, in …

46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

"Designs the immunotherapy of tomorrow" At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders. We're developing a breakthrough cell therapy platform with the potential to: • Replace transplants: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • Expand access for all: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • Dramatically reduce costs: By streamlining production, we aim to significantly lower the cost of cell therapies, …

Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An innovative drug discovery technology Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure …

37 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Swalife Biotech, we are at the forefront of developing next-generation therapies for cancer and chronic diseases. Our research is rooted in the discovery of five novel bioactive alkaloids from plants, aimed at synthesizing compounds that target key mechanisms in skin and breast cancer. We leverage cutting-edge technologies such as network pharmacology and AI to enhance our understanding and development of drug therapies. Our alkaloids have shown promising results in inhibiting the DNA Damage Response (DDR) pathway, crucial in preventing drug resistance and cancer cell survival. Our innovative approach not only targets cancer but also extends to managing chronic diseases, …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Bio sourced materials

We are building the world’s leading predictive simulation of patient biology. Truly meaningful medicine comes from breakthroughs?in deeply understanding patient biology. We are building the world’s first open simulation platform of patient biology. Drug Discovery, Biotechnology, Artificial Intelligence, in silico, Cell Biology, Simulated Experiments, Bioinformatics, and Pharmaceuticals

180 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Digital bio-solutions designed to support the development of biomedicines and optimize their prescription. mYXpression is an innovative French company positioned in the field of health innovation. The company, specialized in R&D, develops innovative tools to assist in the prescription of biomedicines. Its first tool, the RITI® RA test, provides a personalized report specific to the patient by indicating an efficacy score for each biotherapy. This brand new approach provides numerous useful insights to the doctor by assisting in the prescription of biotherapy in order to increase the patient's chances of remission. bio-numérique, innovation technologique, big data, bio-technologie , biotherapie, intelligence …

59 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I.

Transforming health, healthcare and drug discovery through the power of genomics We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalised estimates of risk for all the common diseases and cancers, well ahead of …

81 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics

MD Start is a fund, a team of entrepreneurs and an incubator combined, aimed at transforming innovative ideas into medical realities. Our mission is to incubate medical device innovations to the point where proof-of-principle in patients is demonstrated, allowing for interest from traditional investors and our continued funding. Our team operates the projects and new companies to bridge the gap between science and clinical experience. We source innovations that are too early for large corporate or venture investors. These inventions arise from clinicians all over the world who do not wish to become entrepreneurs Our ambition is to turn these …

95 similar entities Type: Incubators & VCs SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Accelerating biomedical research by connecting biopharmas with the right preclinical cancer models and CRO partners Repositive is committed to accelerating the development of precision cancer therapies to the clinic by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of pre-clinical cancer research. Through its Cancer Models Scout service, Repositive is helping biopharmas to optimise their pre-clinical cancer projects by identifying the most suitable cancer models for their requirements from its world-leading database of over 8000 models, as well as via outreach to an extended network of CRO contacts. Repositive works to connect researchers with the right …

60 similar entities Type: Startup Activities: biotech it services deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the road to precision medicine by tumor characterization via high resolution proteomic profiling. Worldwide, there are more than 20 million new cases of cancer each year. First-line therapies are not always the most effective and there is a strong need to move towards personalized medicine by offering the patients the best treatment as quickly as possible. This will help in increasing the chance or cure. Therefore, there is a need to improve the prediction of the response to treatments to be able to save patient’s lives and reduce the cost of expensive inefficient treatments. Our goal is to unlock …

Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Tarian Pharma's mission is to develop new drugs that ensure optimized cancer treatment by protecting cancer patients from side effects that would lead to dose reductions or discontinuation. This approach is designed to increase patients' chances of recovery and survival. Tarian Pharma was created by two dermatologists and a pharmacist, with more than 75 years of experience in the pharmaceutical industry and having been actively involved in the development and marketing of more than 15 new drugs in Europe, the United States and Asia.

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are invested partners in your success, in bringing life-changing innovations to market With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world’s most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through …

37 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Enabling Success Sygnature Discovery, headquartered in Nottingham (UK), is a world-leading contract research organization for drug discovery. Based in the UK (Nottingham, Alderley Park, Macclesfield, Glasgow) and Canada (Montreal, Laval, Quebec) and with a staff of over 1,000, including over 900 scientists, Sygnature Discovery partners with the global pharmaceutical industry, biotechs and NfP organizations wishing to outsource part of their R&D work. Since 2004, Sygnature Discovery has delivered more than 56 new preclinical compounds, 29 clinical compounds and 1 registered, thanks to the talents of its world-class scientists, who are named on more than 500 patents. The services offered to …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments. Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused …

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading CRO in preclinical research with cutting-edge humanized mouse models for drug development. Rethinking preclinical research - with your goals in mind. TransCure bioServices accelerates drug development by delivering the right models, the right data, with the right partnership mindset. Our advanced humanized mouse models provide robust, translational in vivo results to guide decision-making in: • Oncology (Human CDX, Human PDX, Syngeneic Models) • Inflammatory diseases (IBD, MASH, GvHD, Lung Inflammation) • Infectious diseases & toxicity (HIV, HBV, Immunotoxicity, Hepatotoxicity) You know your drug. We know how to test it. Every study is co-designed with your team to fit your …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Twist your mind think muscle Metabrain Research is a Biopharmaceutical company developing innovation for Health Industry. We develop preventive and / or therapeutic solutions to cure pathologies linked to metabolic aging (Obesity, Diabetes, NASH, Sarcopenia, Depression and Cognitive Decline). We rely on a collaborative research technology platform combining a large number of expertise (medicinal chemistry, Biology and Pharmacology, Drug Discovery & Development, Nutraceuticals, ...). NASH, Sarcopenia, Obesity, Drug Discovery & Development, Nutraceutical, Biology & Pharmacology, Medicinal chemistry, Cognitive decline, Diabetes, Research&Development, Aging, CRO, Vitro-Vivo models, Active Aging, Metabolic Disorders, Muscle, IA, Cardiorenal disease, and Artificial intelligence

33 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I.

Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, …

84 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting diseases at their molecular roots Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The mechanisms of action underlying our approach enables us to target a variety of disease areas with high medical need. With historic roots in diabetes research and development as well as neurodegenerative disorders, Vivoryon’s focus …

Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Fast-track your pipeline with preclinical excellence. in vitro & in vivo research services since 1991. At a glimpse ETAP-Lab is a French preclinical CRO with over 30 years' expertise in derisking research & advancing drug development for pharmaceutical and biotech companies. Our expertise covers dermatological, cardiological, neurovascular and neurological diseases thanks to our dedicated research labs. Our range of services • A portfolio of over 60 tried-and-tested in vitro and in vivo reference models. • Proof of concept & pharmacological experiments • Efficacy & safety studies Working with us • Personalized & expert advisory • Tailor-made & flexible study designs …

38 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Driving Precision Medicine Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated …

45 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Data Analytics

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

294 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Guiding clinicians towards personalized treatment and enhancing quality of life for patients Using molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe.

65 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Pinpoint Gene Therapy At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform called HERMES, delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs …

16 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Vital new drugs for pandemic infections We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections. Pharmaceuticals, R&D, Antimicrobial Resistance, and Development

110 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Life-Transforming Medicines for Patients Living with Serious Rare Diseases VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and …

104 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creativ-Ceutical provides strategic pricing, market access and health economics consulting in life sciences. We provide both the strategic advice and the technical services to deliver results that meet your expectations. We have broad experience in the areas of central nervous system (CNS), oncology, vaccines, metabolic/cardiovascular diseases, and rare diseases. These are complex and developing fields, where treatment paradigms are in constant evolution and where clinical and economic issues require rigorous analysis to determine the best therapeutic choices. This experience allows us to address the most complex challenges and to anticipate pricing and market access issues that will arise in other …

72 similar entities Type: SMB Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our …

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering DARPin Therapeutics for Patients Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA. DARPins, Oncology, Immuno-Oncology, Radiopharmaceuticals, …

82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A revolution in gene therapy for neurodegenerative disorders. At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering …

50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Macrophage Cell Therapy for Transformative Outcomes in Inflammatory Organ Diseases Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. The company was founded following a productive collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, and is backed by Syncona. Our initial focus is in chronic liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, …

29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are Purespring. We are on a mission to radically transform the treatment of kidney diseases. Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases. biotechnology, gene therapy, and kidney diseases

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A reliable clinical development partner CRO, synchronizing endpoints with funding milestones, ensuring impactful trials 🤝ILife Consulting is an entrepreneurial CRO partner specializing in early-phase clinical development. With over 25 years of experience and more than 30 clinical trials supervised, our team of experts transforms clinical data into value-creating assets for your company. We support over 20 active clients, including leading biotechs such as ImCheck, Peptinov, Smart Immune, and Brenus Pharma, as well as prestigious clinical sites like Gustave Roussy. Our expertise in First-in-Human and Proof-of-Concept studies enables us to generate critical data that enhance the value of your assets and …

45 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Reconcile the time of Research with the one of Medecine APTEΞUS was created to provide clinicians and their patients suffering from orphan diseases, an innovative service of clinical biology that perfectly meets the emerging challenge of individualized medicine. APTEΞUS is engaged in patient-centric discovery of individualized treatments. Our technology allows the testing of thousands of molecules directly on primary cells sampled from patient with inborn error of metabolism. We can rapidly identify molecules that specifically correct the very molecular defect of the patient and give him a new opportunity to be cured.

35 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Catalyzing the development of transformative genetic-based therapeutics from concept to clinic. Dedicated to discovery + translational research and led by Dr. James Wilson, the Gene Therapy Program (GTP) at the University of Pennsylvania focuses on the development of next-generation gene transfer vectors and their application in the treatment of a variety of acquired and inherited diseases. Dr. Wilson's commitment to patients with rare diseases stems from his days as a graduate student and medical student at the University of Michigan between 1977 and 1984. He was discouraged by the lack of available treatments for rare disease patients, but optimistic that …

12 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Reach New Heights With Your Biomarkers At OakLabs Scientific, we believe that each of us can live longer healthy. In a society where individual healthcare is increasingly challenging, we are pioneering ways to detect and avert disease before it occurs. Using our unique Artificial Intelligence algorithms and high-molecular-weight data, we are exploring individual health status in unprecedented depth. gene expression analysis, biotechnology, research, biomarkers, biomarker signatures, and companion diagnostics

84 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and …

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The box that takes care of yourself. French drug laboratory 🇫🇷 Biogaran was founded in 1996, to specifically respond to the development of a new market that is still unknown: generic drugs. Offering patients with recognized quality drugs whose patent fell into the public domain then was a new type of know-how that traditional laboratories did not have. Our know-how is available through different ranges: small everyday ailments with the Biogaran Conseil® range, to heavier pathologies with prescription drugs. Whatever pathology, patient health is at the heart of biogaran concerns and the same rigor is brought to the development of …

55 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

CRO specializing in real life data Kappa Health was born from the desire to provide quality services in the fields of epidemiology, pharmaco-epidemiology and public and digital health interventions. The company was founded at the end of 2002 and is based in Paris KAPPA Santé is an independent CRO, a member of the ENCPPP (European Network of Centers for Pharmacoepidemiology and Pharmacovigilance), AFCRO (French Association of CRO), Oséo Excellence (Community of Entrepreneurs chosen by Oséo) and the Cap Digital competitiveness cluster. Today we have participated in more than 100 studies in many therapeutic areas Public health, pharmaco-epidemiology, medical devices, intervention …

Type: SMB Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, and Chemical process research

128 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

196 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

What If You Could Repair Broken Genes? What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One …

28 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

A Sustainable Platform for Specialty Pharma. As a globally operating company headquartered in Germany, CHEPLAPHARM has established a leading and sustainable platform for specialty pharma during the past two decades. We invest worldwide in well-established pharmaceutical brands which have been developed and introduced by research-based pharmaceutical companies. Our deep expertise in this field enables us to sustain the value of these brands for patients and the medical community. In this way we help the research-based pharmaceutical industry divest from older products so they can focus resources on innovation and new product pipelines. This is how we ACHIEVE MORE together. Specialty …

66 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Exploiting the conformational complexity of GPCRs to innovate drug discovery Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals …

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Embleema is the regulatory-grade health data platform to accelerate new drug discovery and release new treatments sooner Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project …

29 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Blockchain/Cryptocurrency

Accelerating the world's transition to precision medicine. At Sano, our mission is to accelerate the world's transition to precision medicine. Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients. Genetics, Big Data, and Research

39 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Pelago Bioscience At Pelago Bioscience, we’re here to help you make faster, better-informed decisions in drug discovery. In 2010, our founders began to develop our proprietary CETSA® (Cellular Thermal Shift Assay) technology, publishing a seminal research paper in Science 2013. Since then, Pelago Bioscience has become the leading CRO providing actionable, biologically relevant insights at the pre-clinical stage.Unlike traditional methods, CETSA gives you a reliable picture of drug-target interactions, ensuring that what you see in cells translates to patients. Our services rest on four pillars: • Certainty in Biological Relevance: CETSA’s physiological approach helps minimize late-stage risks. • Fast & …

17 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expert in target deconvolution for drugs, protein-protein interactions and single-domain antibodies Who else knows your drug or protein better than you? Who else knows protein interactions better than us? Hybrigenics Services is a complete solution provider of cutting-edge technologies dedicated to the study of protein interactions and target identification for drugs. We are also proud to now offer a unique, proprietary nanobody selection service. We help researchers: - Understand proteins'​ functions through the elucidation of their interactions - Characterize precisely a known interaction (map critical domains or amino-acids...) - Identify the targets of small molecules of therapeutic interest - Predict …

37 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We bring life-saving genomics to hospitals, physicians and patients everywhere. Quantgene decentralizes genomics to bring precision medicine to everyone. Our turnkey genomics platform empowers hospitals to move life-saving genomic diagnostics inside their organizations, unlock powerful new sources of revenue and become a driving force in clinical discovery. From complete genomic profiling to hereditary cancer testing and multi-cancer early detection, we help hospitals, physicians and patients to unlock the full power of precision genomics. Cancer diagnostics, biotechnology, genomics, machine learning, oncology, precision medicine, cancer screening, deep sequencing, cancer, innovation, AI, and Cancer Detection

89 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

AI-driven precision medicine for complex, chronic diseases. Creating better diagnostics & more personalized treatments. PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases. Our AI-led platform is unparalleled in its understanding of disease biology. Identifying underlying causes of disease and biomarkers to stratify patients by molecular mechanism. Our unique insights and mechanstic® tests accurately link individuals to the drug targets, clinical trials and treatments that will benefit them - increasing the probability of success in drug development and leading to earlier, more accurate and effective …

46 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, …

111 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

At Maze, we envision a world where genetic insights inspire new medicines. Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. The company’s pipeline is led by two wholly owned lead …

17 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

45 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Eurofins Discovery offers you a complete, single-source solution for drug discovery products and services. Eurofins Discovery has supported Drug Discovery research for >40 years. Our partners inspire us to innovate in the pursuit of life-changing cures. We provide our experience, depth, and breadth in the form of innovative testing services and product tools that support researchers as they accelerate the discovery and development of candidate molecules. Our global team of dedicated scientists, information analysts, and client support professionals make this mission possible. Our focus drives us to continually expand our portfolio of testing methods, tools, and services to enable real, …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empowering patients to bridge rare disease research and trials through a revolutionary clinico-genomic databank. Backed by VCs and an IUK government grant, GeneHub is building the world's first patient-controlled, clinico-genomic databank to bridge rare disease research and clinical trials. GeneHub enhances patient visibility and engagement by elevating patients into verified, zero-party data partners equipped with longitudinal real-world data from primary and secondary care. To ensure privacy, patients must consent to researchers analysing their anonymised clinico-genomic data in secure, on-demand, clean rooms. Patients actively engaging with researchers benefit from free advanced diagnostics such as DNA and mRNA sequencing, accelerating clinical trial …

12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Connecting Brains WE ́RE NOT CURRENTLY HIRING MISSION & VALUES To serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. We value partnership and Integrity, we are ethical and responsible and show respect and compassion for our patients. R&D STRATEGY The successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. R&D is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. The advancements in science mean that more targeted, more (cost-)effective treatments are within …

14 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Disruptive Therapies for Aging Diseases Topadur Pharma AG is a Swiss biopharmaceutical start-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. Topadur’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions. Topadur has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases like chronic …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing therapies for severe leukodystrophies Overview SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases. SynaptixBio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system. Pharmaceutical, Biotech, Leukodystrophy, Rare Disease, H-ABC, Hypomyelination, Basal Ganglia, Cerebrllum, Neurology, …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are a Swiss company on a mission to combat sepsis through magnetic blood purification. Member of @Wyss Zurich. We are a start-up medical device company originating from ETH Zurich and are passionate about developing life saving therapies. Our mission is to develop a breakthrough medical device for the most urgent healthcare issues. Focusing on patients’ needs, we translate the most promising research to the clinics and ensure patient access to scientific progress as soon as possible. As pioneers we take courageous decisions and are shaping the future of medicine. We first focus on finding an efficient therapy for patients …

80 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Expertise that matters Mercodia utilizes its 30+ years of experience as a world-leading manufacturer of cardiometabolic immunoassays to provide tailored bioanalysis solutions for pharma and biotech companies. We specialize in assay development and validation, PK/PD, immunogenicity testing, and biomarker testing, mainly focusing on large molecules, peptides, and oligonucleotide therapeutics in preclinical and clinical development. We are GLP-certified and work in accordance with ICH GCP, EMA, and FDA guidelines. Our team of expert scientists quickly provides reproducible, reliable, and high-quality data that meets regulatory requirements. We prioritize speed and flexibility while delivering cost-effective solutions. Our vision is to improve human health …

140 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We personalise prescribing by matching medication to patient data and DNA. Empowering doctors to say 'this drug is not for everyone, but it is for you. Founded in 2012, we are a London based start-up committed to personalising medicine. To achieve this, we've built a strong team with extensive expertise in pharmacogenetics, pharmacology, big data analytics, business strategy, the NHS and creative design. Pharmacogenetics, Personalised Medicine, Bioinformatics, CPOE, Big Data, and Design

78 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Data Analytics

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications

290 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

98 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The First Cell-Centered Computational Model of Human Disease CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain …

79 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster. Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ascend is an advanced therapy development partner with a flexible platform featuring industry-leading analytics. Ascend is gene to GMP partner with deep expertise in advanced therapy development and commercialization. We offer unparalleled collaboration backed by expertise while working to develop your products from the bench through the clinic and beyond. Let’s build the future of advanced therapies together!

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

DNA-based Digital Twin to help predict and prevent diseases and adverse reaction to drugs Personal genomics solution for predictive medicine—Thanks to unique and groundbreaking technology, Predictiv identifies the genetic predispositions of an individual on 22,000+ diseases and simulated reactions to 750+ drugs. Now enabling more accurate preventive actions and treatments. genomics, predictive medicine, preventive medicine, heathcare, and biotechnology

67 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

159 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Solving data to enable precision therapy for all Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning A.I.

Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Discovering the true signals of disease to power life-changing medicines. 90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that with better, faster drug target discovery powered by the Newfoundland founder effect. Biotechnology and Drug Discovery

90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Boost your program in Oncology We offer professional support all along the drug development life cycle, from lead optimization to Phase I clinical trials in oncology. We optimize and accelerate your R&D programs, based on our drug positioning-oriented philosophy. Early Drug Development Group is focused on building partnerships and strategic alliances with academic research institutions, universities, governmental agencies, small size biotechnology partners and investment funds. COLLABORATION WITH US IMPROVES YOUR RESOURCES INVESTMENT AND STRENGTHENS YOUR EARLY DRUG DEVELOPMENT PROGRAM IN ONCOLOGY. YOUR KEY BENEFITS • Assistance on preclinical, pharmacological and CMC approaches, clinical studies design, regulatory strategies and trials implementation …

17 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

European Mammalian CRDMO - From Discovery mgs to Clinical GMP kgs. We're a leading European biotechnology company, providing streamlined or custom-tailored services for global clients in pharmaceutical, biotechnology industries, and academia. We've been a privately held family business since 1999, and have grown into a leading mammalian Contract Research, Development, and Manufacturing Organization (CRDMO). The CRDMO approach allows us to cover the entire spectrum of pre-clinical and clinical services - from the initial stages of target discovery and development, to cell line development, and manufacturing of mammalian therapeutic proteins, up to 1000 L scale. In 2023, we worked with more …

136 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

605 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology